Harnessing the Immune System to Turn Cold Tumors Hot
We seek to enhance the response rate to checkpoint inhibitors through a combination treatment that activates the immune defense mechanisms to seek out and kill cancer cells.
Heat’s “one-size-fits-all” TCAP approach offers many advantages to autologous or personalized therapies
Custom manufacturing is not necessary, resulting in a much lower cost of good sold than autologous therapies.
Harvest cancer or cells through leukopheresis, reprogramming and reinfusing them back into patient
Personalized, autologous treatment approaches often require surgery to remove a tumor sample in order to isolate a patient’s T-cells, genetically modify them and inject them back into the patient. In the case of CAR-T therapy, the method requires harvesting a patient’s white blood cells to be reprogrammed and then reinfused back into the patient.
Our products are off-the-shelf and ready to use. Patients may begin treatment immediately without having to wait many weeks or months for personalized processing.
These methods can take a month or longer to complete before the drug product can be injected into the patient.
Absolutely nothing extracted from patient. Simple intradermal injection takes about 2 minutes.
Patient cells must be harvested through apheresis. Infusion of finished product into patient. Often requires post-treatment monitoring in ICU for up to two weeks.
Fully scalable production enables us to price our TCAP products competitively.
Our TCAP therapies have been shown to stimulate an immune response against the full antigenic repertoire of cancer cells, not just one or a handful of antigens. They are designed to combine broad antigen targeting of known and unknown tumor-associated antigens complexed with a potent immune adjuvant. The activated immune response generated by our TCAP therapies may be useful in treating a wide range of cancers and infectious diseases.
Our approach is designed to deliver effective immune activation at a much lower cost of goods sold than autologous or personalized therapies. The high cost of these personalized treatments is highlighted in the Wall Street Journal graphic below.
"The Million Dollar Cancer Treatment, Who Will Pay" The Wall Street Journal August 14, 2018